Ignite Creation Date:
2025-12-25 @ 4:26 AM
Ignite Modification Date:
2025-12-26 @ 3:29 AM
Study NCT ID:
NCT07111520
Status:
RECRUITING
Last Update Posted:
2025-10-22
First Post:
2025-08-01
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Sponsor:
BioNTech SE
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Non-small Cell Lung Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Combination with other investigational agents | View |
| None | Programmed death-ligand 1 (PD-L1) | View |
| None | Antibody-drug conjugate (ADC) | View |
| None | Human epidermal growth factor receptor 3 (HER3) | View |
| None | Programmed Death-1 (PD-1) | View |
| None | Programmed Death-1 monoclonal antibodies | View |
| None | Combination chemotherapy | View |
| None | Anti vascular endothelial growth factor-A (anti-VEGF-A) | View |
| None | Bispecific antibody | View |
| None | Immunotherapy | View |
| None | Dose optimization | View |
| None | Time to progression | View |
| None | Vascular endothelial growth factor (VEGF) | View |